News Center
News Type
Kvvit Pharmaceuticals Signs 10-Product Cooperation Deal with Vietnam’s Tasco Pharma Officially Expanding Self-Operated Business Across ASEAN
On June 13, 2026, Jiangxi Kvvit Pharmaceuticals Co., Ltd., a subsidiary of QF Pharmaceutical Group, officially signed a commercial cooperation agreement with Tasco Pharma.
DN022150 Phase I/IIa Data Presented in Oral Presentation Session at the 2026 ASCO Annual Meeting
June 2026 – Kvvit Pharmaceuticals announced that Phase I/IIa clinical data for DN022150, a novel selective noncovalent KRAS G12D inhibitor, for patients with KRAS G12D-mutant locally advanced or metastatic solid tumors who have progressed following prior standard therapies, were presented in an Oral Presentation Session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting on June 2.
Kvvit and Merz Therapeutics Enter Exclusive Agreement for INBRIJA® (levodopa inhalation powder) in mainland China, Hong Kong and Macao
Jiangxi Kvvit Pharmaceutical Co., Ltd. (hereinafter referred to as “Kvvit”), a subsidiary of QF Pharmaceutical Group, announced that it has entered into an exclusive license and collaboration agreement with German pharmaceutical company Merz Therapeutics GmbH for INBRIJA® (generic name: levodopa inhalation powder) and its proprietary inhalation device.
Qingfeng will attend the 2026 J.P. Morgan Healthcare Conference
Qingfeng Pharmaceutical Group will participate in BIO Partnering @ JPM Week 2026, which will take place in San Francisco from January 12–15, 2026.
Kvvit Pharma Unveils Dual Breakthroughs in CNS Therapeutics at Prestigious SfN-2025 Conference
At the Society for Neuroscience 2025 meeting (SfN-2025), Jiangxi Kvvit Pharmaceutical showcased promising data on two drug candidates. KR232 is a next-generation treatment for schizophrenia, and KR233 has best-in-class potential for epilepsy. These presentations highlight Kvvit's growing pipeline focused on unmet needs in CNS disorders.
Single-Dose Treatment! China’s First Novel Antiviral Influenza Drug Yisuda® Approved for Market
On March 27, 2025, Kvvit Pharmaceuticals, a subsidiary of Qingfeng Pharmaceutical Group, received approval to market Yisuda® Suraxavir Marboxil Tablets.
